Scientists have identified a previously unrecognised mechanism through which the immune system can attack cancer cells, a discovery that could lead to new treatment strategies for patients whose tumours resist existing immunotherapies. The findings, published in the journal Nature Immunology, challenge long-standing assumptions about how different immune cells detect and destroy cancer.

For decades, researchers believed that major histocompatibility complex (MHC) class I proteins primarily worked alongside CD8+ T cells, often known as "killer" T cells, to identify and eliminate abnormal cells. In contrast, CD4+ T cells, commonly referred to as "helper" T cells, were thought to play a supporting role by coordinating immune responses rather than directly attacking tumours. The new research suggests that CD4+ T cells may have a much more active role in cancer defence than previously understood.

The study was led by Dr. Pavan Reddy, Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, in collaboration with researchers from the University of Michigan Rogel Cancer Center. Investigating how cancer cells evade immune detection, the team focused on tumours that reduce MHC class I proteins on their surfaces. This tactic allows many cancers to avoid recognition by killer T cells, making them more difficult to target through natural immune responses and some immunotherapies.

Also Read: Pope Leo To Visit Spain And Italy Migration Hotspots In Coming Weeks

However, the researchers found that this apparent escape strategy may come at a cost to cancer cells. When MHC class I levels were reduced, tumour cells became more vulnerable to attacks from CD4+ T cells. These immune cells triggered severe internal stress within the cancer cells, ultimately leading to their destruction. The findings suggest that when tumours evade one branch of the immune system, they may inadvertently expose themselves to another.

The discovery could have significant implications for cancer treatment. Many modern immunotherapies are designed to activate killer T cells, but their effectiveness can diminish when tumours suppress MHC class I expression. Researchers believe therapies aimed at enhancing CD4+ T cell activity could provide an alternative route to targeting cancers that have become resistant to conventional immunotherapy. Dr. Reddy said the findings may help scientists develop treatments that strengthen beneficial immune responses while minimising harmful effects.

Beyond cancer, the study also points to potential applications in understanding graft-versus-host disease (GVHD), a serious complication that can occur after bone marrow transplants. Analysis of patient data further suggested that the newly identified immune response may influence outcomes in people receiving immunotherapy, indicating that the mechanism could have real-world clinical relevance. While further studies are needed, the findings offer promising new insights into how the immune system can be harnessed to fight cancer and other diseases.

Also Read: World Environment Day 2026: Why Meditation In Nature Is Recommended By Experts